Can this diabetes-control breakthrough also become the answer to obesity? From Hollywood’s red carpets to affluent Indians, ...

The Indiana Family and Social Service Administration’s Office of Medicaid Policy and Planning estimates that 5% to 20% of eligible members would be prescribed weight-loss medications.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...

A new quick-and-easy nasal swab test for kids can diagnose the specific immune system drivers behind their asthma, ...

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been ... Additionally, Lilly ...

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...